c-Met inhibitors by Anum Mughal et al.
Mughal et al. Infectious Agents and Cancer 2013, 8:13
http://www.infectagentscancer.com/content/8/1/13LETTER TO THE EDITOR Open Accessc-Met inhibitors
Anum Mughal1, Hafiz Muhammad Aslam1*, Asfandyar Sheikh1,2, Agha Muhammad Hammad Khan3
and Shafaq Saleem1Abstract
c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR).
Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small
molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. Met inhibitors divided into two main classes:
class I (SU-11274-like) and class II (AM7-like). The use of c-Met inhibitors with other therapeutic agents could be
crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors
might be used in combination with other treatments, including chemo-, radio- or immunotherapy
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c-Met is a proto-oncogene that encode a protien known
as hepatocyte growth factor receptor (HGFR) [1-3]. It is
essential for embryonic development, wound healing
and organ morphogenesis [4,5]. MET is a membrane re-
ceptor. It stimulates cell scattering, invasion, protection
from apoptosis and angiogenesis [6]. MET is normally
expressed by cells of epithelial origin [4]. Deregulated ac-
tivity of c-Met can cause a wide variety of different can-
cers, such as colorectal, thyroid, renal cell, ovary, breast,
pancreas, prostate, liver, and melanoma and in gastric
carcinoma [7-11].
Hepatocyte growth factor (HGF) is the only known lig-
and of the MET receptor [4,5,12]. Upon HGF stimulation,
MET induces MET kinase catalytic activity which triggers
transphosphorylation of the tyrosine Tyr 1234 and Tyr
1235. These two tyrosines engage various signal transduc-
ers, thus initiating a whole spectrum of biological activities
driven by MET, collectively known as the invasive growth
program. Over expression, gene amplification, mutation, a
ligand-dependent auto- or paracrine loop or an untimely
activation of RTK leads to c-Met dysregulation [4,13].
Cancer development is closely associated with different
oncogenic pathways. RAS pathway mediates scattering
and proliferation signals which lead to branch morpho-
genesis [14]. PICK3 pathways activates either directly or
through down stream of RAS pathway [15]. Beta catenin* Correspondence: coolaslam8@hotmail.com
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reproduction in any medium, provided the orpathway participates in transcriptional regulation of nu-
merous genes while NOTCH pathway activates through
Delta ligand [16,17]. Activation of these oncogenic path-
ways (RAS, PI3K, STAT3, beta-catenin), angiogenesis
and cells dissociation due to metalloprotease production,
which often leads to metastasis, are involved in the devel-
opment of cancer [18].
c-Met inhibitors are relatively new class of small mole-
cules that inhibit the enzymatic activity of the c-Met
tyrosine kinase. Pyrrole-indolinone (PHA-665752) is a
prototype selective class of inhibitors that inhibits HGF/
SF-induced receptor phosphorylation [4,5,19]. There are
basically two classes of c-Met inhibitors, ATP competi-
tive and ATP non-competitive inhibitor. ATP competi-
tive inhibitors are further divided into two classes; class
I (SU-11274-like) and class II (AM7-like) on the basis of
different types of binding and a third group of non-
competitive ATP inhibitor that binds in a different way
to the other two [20,21]. Class I inhibitors are selective,
U-shaped and attached to the activation loop of c-Met.
JNJ-38877605 ( for advanced and refractory solid tu-
mors) and PF-04217903 are class I met inhibitors that
underwent phase I clinical trials in 2010 [22]. Class II in-
hibitors have urea group in either cyclic or acyclic form.
Foretinib XL880 is a class II met inhibitor that targets
multiple tyrosine kinases, primary targets are MET,
VEGFR2 and KDR. It has completed phase-2 clinical
trial with indications for head and neck, gastric and
renal cell carcinoma [22,23]. Other candidates undergo-
ing trials include Merck’ MK-2461, Bristol Meyers Squib’l Ltd. This is an Open Access article distributed under the terms of the Creative
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BMS/Exelixis’ XL-184 [12,22].
The Met pathway is one of the most frequently
dysregulated pathways in human cancer [12]. c-Met
inhibitors that are currently in clinical trials include
cabozantinib and foretinib. Cabozantinib (XL184) was ap-
proved by the U.S. FDA in November 2012 for the treat-
ment of medullary thyroid cancer [24]. Patients taking this
medication should not ingest grapefruit or grapefruit juice
as it may increase the concentration of the drug in the
patient's blood [25]. Foretinib is yet an experimental drug
candidate for the treatment of cancer [26].
The use of c-Met inhibitors with other therapeutic agents
could be crucial for overcoming potential resistance as well
as for improving overall clinical benefit. As a key element in
the development of any targeted therapy, the biochemical
and molecular determination of the precise functions of the
Met pathway in the context of other relevant pro-cancer
pathways will undoubtedly play a significant role in this ef-
fort [12]. More implications are likely to be discovered as
new horizons in cancer therapeutics are unveiled [27].
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